Javascript must be enabled to continue!
The Impact of Directors' Option Compensation on Their Independence
View through CrossRef
This study examines how the use of option-based compensation for directors affects their independence in their decisions on CEOs' option-grant dates. Firms typically grant CEOs at-the-money options, i.e., with the strike price set equal to the grant-day stock price. This practice creates a unique opportunity for CEOs to benefit from Timing Opportunism, whereby CEOs lower the grant-day stock price in order to increase the value of their option grants. Prior evidence indicates the existence of timing opportunism, because CEOs tend to receive options before (after) good news (bad news). Since directors frequently receive options at the same time as CEOs, directors also benefit from timing opportunism, so they may not have an incentive to constrain CEOs' timing opportunism. We hypothesize that, ceteris paribus, directors are more likely to constrain CEOs' timing opportunism when these directors receive a lower proportion of their compensation from stock options. We find evidence consistent with our hypothesis in a large sample from 1992 to 2002. Our results indicate that, when used as a common component of CEOs' and directors' compensation, stock options can compromise director independence in this particular setting.
Title: The Impact of Directors' Option Compensation on Their Independence
Description:
This study examines how the use of option-based compensation for directors affects their independence in their decisions on CEOs' option-grant dates.
Firms typically grant CEOs at-the-money options, i.
e.
, with the strike price set equal to the grant-day stock price.
This practice creates a unique opportunity for CEOs to benefit from Timing Opportunism, whereby CEOs lower the grant-day stock price in order to increase the value of their option grants.
Prior evidence indicates the existence of timing opportunism, because CEOs tend to receive options before (after) good news (bad news).
Since directors frequently receive options at the same time as CEOs, directors also benefit from timing opportunism, so they may not have an incentive to constrain CEOs' timing opportunism.
We hypothesize that, ceteris paribus, directors are more likely to constrain CEOs' timing opportunism when these directors receive a lower proportion of their compensation from stock options.
We find evidence consistent with our hypothesis in a large sample from 1992 to 2002.
Our results indicate that, when used as a common component of CEOs' and directors' compensation, stock options can compromise director independence in this particular setting.
Related Results
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Abstract
Introduction
The short half-life of standard factor VIII (FVIII) products means that frequent injections (3 to 4 times/week) are needed for e...
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
Abstract
Background
Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that ...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Introduction: Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single leukemia associated antigen with chimeric antigen receptor T (CAR T) cells ...
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Abstract
Introduction: B cell maturation antigen (BCMA) is a novel target for T cell immunotherapy in MM including bispecific antibody (bsAb) and chimeric antigen re...
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Introduction Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in clinical development for the subcutaneous prophylactic treatment of hemophilia pati...
Board Independence, Nomination and Remuneration Committee, and Compensation in Indonesia
Board Independence, Nomination and Remuneration Committee, and Compensation in Indonesia
This article aims to examine the relationship between independent commissioners and nomination and remuneration committee (KNR) and their interaction with directors’ compensation u...
Plastic Surgery Training and the Problematic Resident
Plastic Surgery Training and the Problematic Resident
Introduction
Plastic surgery resident education is a significant commitment by both programs and residents. Unfortunately, problematic resident behavior may occur and b...

